Twist Bioscience Co. (NASDAQ:TWST) CFO Sells $27,846.00 in Stock

Twist Bioscience Co. (NASDAQ:TWST - Get Free Report) CFO Adam Laponis sold 936 shares of the firm's stock in a transaction on Wednesday, May 21st. The stock was sold at an average price of $29.75, for a total value of $27,846.00. Following the transaction, the chief financial officer now owns 106,018 shares of the company's stock, valued at approximately $3,154,035.50. This represents a 0.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Twist Bioscience Stock Performance

Shares of Twist Bioscience stock traded up $0.10 on Friday, hitting $28.26. The stock had a trading volume of 568,367 shares, compared to its average volume of 1,097,730. The company's 50 day moving average price is $36.96 and its 200 day moving average price is $42.95. The stock has a market cap of $1.69 billion, a price-to-earnings ratio of -8.36 and a beta of 2.54. The company has a current ratio of 4.96, a quick ratio of 4.62 and a debt-to-equity ratio of 0.03. Twist Bioscience Co. has a 52-week low of $27.12 and a 52-week high of $60.90.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last announced its earnings results on Monday, May 5th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.10). Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The business had revenue of $92.79 million for the quarter, compared to analysts' expectations of $92.00 million. On average, research analysts anticipate that Twist Bioscience Co. will post -2.12 EPS for the current year.

Wall Street Analyst Weigh In

TWST has been the topic of a number of recent research reports. Guggenheim reiterated a "buy" rating and set a $50.00 price target on shares of Twist Bioscience in a research note on Tuesday, May 6th. Robert W. Baird reduced their target price on shares of Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating on the stock in a report on Tuesday, May 6th. Barclays dropped their price target on shares of Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating for the company in a research note on Thursday, April 10th. JPMorgan Chase & Co. reduced their price objective on Twist Bioscience from $40.00 to $33.00 and set an "underweight" rating on the stock in a research note on Tuesday, May 6th. Finally, Scotiabank restated an "outperform" rating on shares of Twist Bioscience in a report on Tuesday, February 4th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, Twist Bioscience currently has a consensus rating of "Moderate Buy" and a consensus target price of $50.40.

Institutional Investors Weigh In On Twist Bioscience

Institutional investors and hedge funds have recently made changes to their positions in the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Twist Bioscience by 186.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,442,262 shares of the company's stock worth $95,883,000 after purchasing an additional 1,588,587 shares during the period. First Light Asset Management LLC purchased a new position in Twist Bioscience during the fourth quarter worth about $56,984,000. EdgePoint Investment Group Inc. acquired a new stake in Twist Bioscience in the first quarter valued at about $43,705,000. Marshall Wace LLP boosted its holdings in Twist Bioscience by 15,927.8% in the 4th quarter. Marshall Wace LLP now owns 846,107 shares of the company's stock valued at $39,319,000 after purchasing an additional 840,828 shares in the last quarter. Finally, Nuveen LLC acquired a new position in Twist Bioscience during the 1st quarter worth approximately $31,960,000.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.